youtube
Eli Lilly delivered a massive third quarter earnings beat with 24.4 billion dollars in revenue, fueled by soaring demand for weight loss and diabetes treatments Mounjaro and Zepbound. The pharmaceutical giant raised its full-year revenue outlook by 5.5 billion dollars, demonstrating unmatched momentum and industry-leading profitability compared to peers like Merck. However, Seeking Alpha's Quant Rating currently rates Eli Lilly a Hold due to an F grade in valuation, driven by exceptionally rich multiples. While metabolic therapies continue to supercharge top-line growth, near-term cost charges are compressing net guidance, leaving investors to weigh explosive growth against an expensive stock price.
|
